Successful Completion of Phase 2a Study in Celiac Disease
Successful Completion of Phase 2a Study in Celiac Disease
Reversibly acting TG2 inhibitors
Reversibly acting TG2 inhibitors
Drug candidates for the treatment of fibrosis
Successful Completion of Phase 2a Study in Celiac Disease
Reversibly acting TG2 inhibitors
Drug candidates for the treatment of fibrosis
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
Press release: Zedira announces ISO 9001:2015 certification
Design of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering